IL319748A - Pcsk9 inhibitors and methods of use thereof - Google Patents

Pcsk9 inhibitors and methods of use thereof

Info

Publication number
IL319748A
IL319748A IL319748A IL31974825A IL319748A IL 319748 A IL319748 A IL 319748A IL 319748 A IL319748 A IL 319748A IL 31974825 A IL31974825 A IL 31974825A IL 319748 A IL319748 A IL 319748A
Authority
IL
Israel
Prior art keywords
methods
pcsk9 inhibitors
pcsk9
inhibitors
Prior art date
Application number
IL319748A
Other languages
Hebrew (he)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL319748A publication Critical patent/IL319748A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL319748A 2022-09-23 2023-09-22 Pcsk9 inhibitors and methods of use thereof IL319748A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263376791P 2022-09-23 2022-09-23
US202363483797P 2023-02-08 2023-02-08
US202363580500P 2023-09-05 2023-09-05
PCT/EP2023/076197 WO2024062090A1 (en) 2022-09-23 2023-09-22 Pcsk9 inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
IL319748A true IL319748A (en) 2025-05-01

Family

ID=88204310

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319748A IL319748A (en) 2022-09-23 2023-09-22 Pcsk9 inhibitors and methods of use thereof

Country Status (17)

Country Link
US (1) US20240228469A1 (en)
EP (1) EP4590397A1 (en)
JP (1) JP2025532670A (en)
KR (1) KR20250075662A (en)
CN (1) CN120322430A (en)
AU (1) AU2023345563A1 (en)
CA (1) CA3268338A1 (en)
CL (1) CL2025000822A1 (en)
CO (1) CO2025004968A2 (en)
CR (1) CR20250143A (en)
DO (1) DOP2025000067A (en)
IL (1) IL319748A (en)
MX (1) MX2025003126A (en)
PE (1) PE20251755A1 (en)
TW (1) TW202430178A (en)
UY (1) UY40445A (en)
WO (1) WO2024062090A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4786462A1 (en) * 2023-09-25 2026-08-05 Shenzhen Salubris Pharmaceuticals Co., Ltd. Pyridone compounds and preparation method therefor, and application
TW202539678A (en) * 2024-03-20 2025-10-16 瑞典商阿斯特捷利康公司 Pcsk9 inhibitors and methods of use thereof
TW202602886A (en) * 2024-03-20 2026-01-16 瑞典商阿斯特捷利康公司 Pcsk9 inhibitors and methods of use thereof
WO2025214500A1 (en) * 2024-04-12 2025-10-16 上海翰森生物医药科技有限公司 Free base crystal form of nitrogen-containing heterocyclic derivative, acid salt and crystal form thereof, preparation method therefor, and use thereof
TW202612699A (en) * 2024-05-16 2026-04-01 瑞典商阿斯特捷利康公司 Combination therapy
WO2026044073A1 (en) 2024-08-22 2026-02-26 Avioris Bio, Inc. Pcsk9 inhibitors and methods of using the same
WO2026086805A1 (en) * 2024-10-23 2026-04-30 深圳信立泰药业股份有限公司 Pcsk9 and hmg-coa bicyclic compound, and preparation and use thereof
WO2026092600A1 (en) * 2024-10-31 2026-05-07 石药集团中奇制药技术(石家庄)有限公司 Nitrogen-containing heterocyclic compound and use thereof
WO2026109026A1 (en) * 2024-11-25 2026-05-28 深圳信立泰药业股份有限公司 Pcsk9 and lp(a) dual-target compound and use thereof
WO2026131688A2 (en) 2024-12-16 2026-06-25 Astrazeneca Ab Crystalline forms and methods of synthesis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202134D0 (en) 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (en) 2019-01-18 2021-09-21 Astrazeneca Ab PCSK9 INHIBITORS AND METHODS OF USING THEM
WO2023084449A1 (en) * 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder

Also Published As

Publication number Publication date
KR20250075662A (en) 2025-05-28
MX2025003126A (en) 2025-06-02
UY40445A (en) 2024-02-15
EP4590397A1 (en) 2025-07-30
JP2025532670A (en) 2025-10-01
CL2025000822A1 (en) 2025-06-23
US20240228469A1 (en) 2024-07-11
DOP2025000067A (en) 2025-06-30
CA3268338A1 (en) 2024-03-28
CR20250143A (en) 2025-06-10
TW202430178A (en) 2024-08-01
AU2023345563A1 (en) 2025-05-01
CN120322430A (en) 2025-07-15
PE20251755A1 (en) 2025-07-09
WO2024062090A1 (en) 2024-03-28
CO2025004968A2 (en) 2025-05-19

Similar Documents

Publication Publication Date Title
IL297625B2 (en) PI3K-alpha INHIBITORS AND METHODS OF USE THEREOF
PT3911648T (en) Pcsk9 inhibitors and methods of use thereof
CA3268338A1 (en) Pcsk9 inhibitors and methods of use thereof
IL327523A (en) Ras inhibitors and methods of use thereof
GB2595975B (en) Inhibitors of cysteine proteases and methods of use thereof
IL320388A (en) Macrocyclic kras inhibitors and methods of use
IL312348A (en) Inhibitors of hif-2alpha and methods of use thereof
IL284661A (en) pcsk9 inhibitors and methods of using them
IL318169A (en) Inhibitors of apol1 and methods of using same
IL316619A (en) Pi3kα inhibitors and methods of use thereof
IL321357A (en) Inhibitors of kif18a and uses thereof
IL314320A (en) Compounds and methods of use
EP4370124A4 (en) PI3Ka INHIBITORS AND METHODS OF USE THEREOF
IL299700A (en) KCNT1 inhibitors and methods of use
IL314330A (en) APOL1 inhibitors and methods of use
IL318393A (en) Aza-quinazoline compounds and methods of use
EP4329735A4 (en) Kcnt1 inhibitors and methods of use
SG11202101618PA (en) Arginase inhibitors and methods of use thereof
IL314277A (en) Anti-b7-h3 compounds and methods of use
LT4168409T (en) Vmat2 inhibitors and methods of use
IL321255A (en) Adar1 inhibitors and methods of using the same
IL327384A (en) Cbl-b inhibitors and methods of uses thereof
HK40127572A (en) Pcsk9 inhibitors and methods of use thereof
IL320186A (en) Ccr2 inhibitors and methods of use
HK40108854A (en) Kcnt1 inhibitors and methods of use